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Abstract:
In this retrospective review, metabolic factors present in diabetic patients who underwent
bariatric surgery were compared against those who were treated with medical therapy alone.
These factors include: diabetes remission, glycosylated hemoglobin levels, medication use,
changes in beta cells function, insulin sensitivity, incretin levels, weight loss, lipid profiles and
blood pressures. Following bariatric surgery, patients observed superior changes in diabetes
remission rates, glycosylated hemoglobin levels, medication use, beta cell function, insulin
sensitivity, incretin levels, and weight loss when compared to those who were treated with
medical therapy alone. Blood pressure changes were not significantly different among the two
treatment groups. Between 3-5 years after surgery, the surgical group showed significantly lower
levels of low-density lipoproteins, total cholesterol, and triglycerides. In addition, high density
lipoprotein values were raised in greater amounts following bariatric surgery. Diabetic patients
who undergo bariatric surgery report higher amounts of minor complications following surgery
than those who are not diagnosed with diabetes. This paper also examined the side effects and
safety of bariatric surgery to determine associated risks and benefits. Nutritional deficiencies,
bone metabolism, dumping syndrome, and surgical complications should be considered potential
risk factors by patients who are considering bariatric surgery to treat their diabetes. Benefits
following surgery include a decreased death rate from coronary artery disease, diabetes, and
cancer.

Introduction:
The prevalence of diabetes has nearly doubled between 1980 and 2014 worldwide. 1
Increases in diabetic populations are seen in low to middle income countries and in men more so
than women.1 This chronic and highly prevalent disease was estimated to be affecting 415
million people globally in 2015 and is predicted to rise to 642 million by 2040.2 Type 2 diabetes
is by far the most common type of diabetes (>90%)3 and is defined as elevated blood glucose due
to progressive insulin resistance leading to decreased beta cell function.
It is a common belief among researchers that a sedentary lifestyle and Western style diet1
are among the most prevalent risk factors for developing type 2 diabetes. These two factors are
also associated with increased risk of developing obesity which is commonly noted as a
complication for type 2 diabetic patients.1 Other literature suggests environmental factors, gut
microbiome, and genetics as possible risk factors of developing type 2 diabetes as well.The list
of sequelae from diabetes is long and often complicated by other comorbid risks. Diabetes is
often associated with an increased mortality rate greater among women than men when
compared to those without diabetes.4 If you examine patients who are diagnosed with diabetes
and morbid obesity (BMI > 35 with comorbidities, or BMI >40 without comorbidities) then
mortality rates show a two-fold excess when compared to lean subjects.4
Current diabetes treatment recommendations modeled by the American Association of
Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) have a
comprehensive and multifaceted approach including lifestyle changes focused on diet, physical
activity, sleep, and smoking cessation.5 However this approach seems to be less effective and has
pushed the hand of providers to their prescription pads.5 There are several medications used to

treat diabetes but these medications do not come without their own side effects, risks, and
complications. Up to 90% of patients with type 2 diabetes do not reach treatment goals designed
to reduce significant complications.6 These grim results again lead researchers and providers to
come up with new solutions which is when bariatric surgery s effects on diabetes became a topic
of interest. Currently, based on National Institutes of Health (NIH) guidelines which were last
revised in 1991, only patients with type 2 diabetes and a body mass index (BMI) of 35 kg/m2 or
more are eligible for bariatric surgery.7 Since the NIH recommendations were published a
plethora of new evidence has been generated providing peer reviewed data suggesting that
bariatric surgery has a powerful effect on type 2 diabetes. The data suggests that bariatric
procedures' positive effect on the health of diabetic patients stems from reduced food intake and
healthier body weight as well as weight-independent mechanisms.8 There are several types of
bariatric surgery used in the treatment of diabetes but this article will focus on biliopancreatic
diversion, Roux-en-Y gastric bypass, laparoscopic adjustable gastric band, and sleeve
gastrectomy.
This review article will examine how intensive medical management compares to
bariatric surgery modalities in the treatment of diabetes paying special attention to their efficacy
in glycemic controls and effects on related comorbid disease risk factors. In addition, this article
will examine the safety and adverse effects of bariatric surgery that are currently keeping some
from exploring it as a treatment option.
Methods:
Using PubMed, Google Scholar, and UpToDate a thorough examination of literature was
done to explore the comparison of intensive medical therapy to bariatric surgery in patients with

type 2 diabetes. In addition to the comparison between the treatment options the same search
engines were utilized to identify articles that included safety, side effects, and complications of
bariatric surgery modalities. The keywords used in this search include “prevalence of diabetes ,
“risk factors for developing diabetes , “diabetes signs and symptoms , “bariatric surgery and
diabetes , “bariatric surgery versus medication in treatment of diabetes , “bariatric surgery
complications , “bariatric surgery and 10 year , “bariatric surgery and safety. Reference lists
were also examined for associated and relevant articles. 10 articles were identified and utilized as
references for comparison between medical management and bariatric surgery while 6 articles
were analyzed that addressed the safety, side effects, and complications of bariatric surgery. In
addition, 8 articles were examined for specifics of diabetes, bariatric surgery, and background
information. Search options included peer reviewed articles that consisted of randomized control
trials, clinical trials, observational studies, meta analyses, and review articles. Each study
included recent data (within 10 years) except for 1 long term retrospective cohort study from
2007 which gathered mortality rates of bariatric surgery.22 An expert interview was conducted
with Dr Michael McRae on 5/22/2020 via phone and was followed up through emailed prompt
(appendix A). Major inclusion criteria were peer reviewed articles focusing on medical
interventions compared to bariatric surgeries in type 2 diabetic patients, articles that examined
mortality rates and complications of bariatric surgery, and articles that provided information on
how bariatric surgery relates to diabetes control. Exclusion criteria removed articles that included
participants less than 18 years old, pregnant women with gestational diabetes, or included
surgery modalities other than biliopancreatic diversion, Roux-en-Y bypass, adjustable gastric
band, and sleeve gastrectomy. All the articles and data utilized in this review were analyzed and
assessed by the author of this review. Relevant statistically significant findings and information

were extracted and investigated. The quality of each study was evaluated by the type of design,
relevant information, selection biases, and how their conclusions compare to current literature.
Background: Literature Review
Diabetes mellitus (DM) is a metabolic disorder in which patients suffer from high blood
sugar levels because their bodies do not respond to, or just simply lack, insulin.9 Insulin is a
hormone secreted by the beta cells within the pancreas that signals the body to uptake glucose
into the cells in response to increased blood glucose levels. In addition, this hormone inhibits
hepatic glucose production which lowers blood glucose levels.9 Type 2 diabetes can be defined
as an over stimulation of receptor cells from constant elevated blood glucose levels. Eventually
this leads the body to have a decreased sensitivity to the insulin being secreted. 9 This review will
only focus on patients with type 2 diabetes and how bariatric surgery affects glycemic control
and outcomes. In the chronic setting diabetes can lead to renal failure, blindness, diabetic foot
disorders, neuropathies, and cardiovascular diseases. 9 Despite significant effort from the medical
community, diabetes has remained the 5th leading cause of death worldwide.9 Diabetic patients
have a reported 15% increased risk of premature death and their life expectancy is decreased by
20 years when compared to those without the disease.9
The American Diabetes Association (ADA) recommends that screening for diabetes
begins for all people at age 45 and is repeated every three years. Screening tests include: fasting
plasma glucose test (FPG), random glucose test , glycosylated hemoglobin level (HbA1c), and an
oral glucose tolerance test (OGTT).10
Due to the complexity of diabetes, medical professionals implore multifaceted treatment
plans consisting of lifestyle modifications, medications, and bariatric surgery as a common last

resort. Intensive medical therapy to treat diabetes may be defined as a combination of lifestyle
changes and medications that align with the goals and standards within current literature.
Medications are often prescribed based on glycemic control, lipid control, patient tolerability,
and efficacy. The most common medication classes used in the treatment of diabetes are
Biguanides, Sulfonylureas, Thiazolidinediones, Alpha Glucosidase inhibitors, DPP4 inhibitors,
Amylin Mimetics, and Insulin. Due to the individual nature of diabetes treatment plans specific
medications utilized for glycemic, blood pressure, or lipid control will not be identified nor were
they individually tracked among the studies.
Bariatric surgery is a horizon term and can be used to describe several surgical
procedures including laparoscopic adjustable banding (ABG), Roux-en-Y gastric bypass
(RYGB), sleeve gastrectomy (GS), and biliopancreatic diversion (BPD). Laparoscopic adjustable
banding is defined as an adjustable silicone band being placed around the superior portion of the
stomach, creating a small gastric pouch.11 The diameter of the band can be changed by a provider
as needed.11 Roux-en-Y-gastric bypass is a surgical procedure where a small, vertically oriented
pouch is made from the superior portion of the stomach.11 This pouch remains connected to the
esophagus at one end and, at the other end is attached to a section of the small intestine, thus
bypassing the remaining gastric contents and the duodenum.11 Sleeve Gastrectomy involves a
surgical diversion of the stomach which is done vertically, reducing the size by about 75%. 11
This procedure is not reversable.11 Lastly the Biliopancreatic Diversion consist of first
performing a distal horizontal gastrectomy.11 This alimentary limb is then anastomosed to the
distal small intestine.11 The bypassed small intestine carrying bile and pancreatic sections is
known as the biliopancreatic limb and is connected to the small bowel proximal to the ileocecal
valve. 11 This small proximal portion is the only limb segment where digestive secretions and

nutrients mix thus this procedure can cause marked malabsorption.11 According to recent
surveying, RYGB and SG account for a large majority of the bariatric procedures currently being
done 45% and 37%, respectively, 11 whereas the use of AGB has fallen to around 10% and BPD
rates are less than 2%.11
The mechanism by which many of these surgical modalities treat diabetes has been a
topic of recent research. It is reported that bariatric surgery induces weight loss which improves
insulin sensitivity among cells, decreases hyperinsulinemia, and improves beta cell function by
weight independent factors related to an incretin effect.12 After bariatric surgery, levels and
activities of proteins which are regulated by insulin, increase. The exact reason behind this
observation is not known but it likely correlated to a change in diet and decreased fat percentage
which is seen in greater abundance following bariatric surgery.12 Due to an increased insulin
sensitivity following bariatric surgery, one study noted significantly increased levels of incretins
over the medical therapy group.12 Incretins are released in response to a patient eating and will
also increase with the secretion of insulin. Incretins are peptides that act by assisting in insulin
secretion and by decreasing glucagon secretion. This is extremely beneficial to patients trying to
control their glycemic levels as glucagon breaks down lipids in the liver to create glucose which
is secreted into the blood. These changes significantly improve glycemic control in patients,
decrease antidiabetic medication use, and hopefully provide diabetes remission. Dr Michael
McRae (appendix A), was asked for his thoughts on how bariatric surgery works in treating type
2 diabetes. His response was “The complete mechanism behind how bariatric surgery improves
outcomes in type 2 diabetes is unclear. Many patients will begin having significant drops in their
blood sugar and insulin requirements immediately following surgery before any weight loss
occurs. The improvement in lipid profiles, blood pressures and blood sugars secondary to weight

loss can be explained by the improvement in insulin resistance. When fat is removed from tissues
such as the liver, muscles, ect. the insulin receptor begins working much better. This allows the
endogenous insulin produced by the pancreas to start working much better and subsequently
improve blood sugar, lipid profiles, and blood pressures.
Currently bariatric surgery is only recommended for diabetic patients if they have a body
mass index (BMI) greater than 35 kg/m2.7 This recommendation is based on the National
Institutes of Health Guidelines which was endorsed by the centers for Medicare and Medicaid. 7
Patients with a BMI less than 35 kg/m2 are simply offered medications and lifestyle treatment
options.7 Millions of patients with type 2 diabetes have a BMI <35; for many of them, metabolic
surgery due to the NIH guidelines is not an option because of the financial burden of being
forced to pay out of pocket for the procedure.7 Without substantial evidence, the NIH is unlikely
to change the bariatric surgery guidelines for patients with diabetes.
Bariatric Surgery VS Intensive Medical Management (Lifestyle
Changes/Medications)
Diabetes remission
Multiple studies have shown a remission of diabetes through bariatric surgery.7,13-15 There
is an increasing number of studies that provide evidence that bariatric surgery shows a superior
efficacy when compared to non-surgical treatment options in causing remission in diabetic
patients. 7,13-15 In general, remission of diabetes is determine by a glycosylated hemoglobin
(HbA1c) level of <6.5%, and a fasting plasma glucose (FPG) less than 126 mg/dl.14 However
each of the following studies provide different definitions of remission which will be reviewed.

Mingrone et al., defined remission as FPG <100mg/dl and a HbA1c <6.5% without the
use of diabetic medication. The study participants were divided into 3 groups, medical therapy
only n=20, RYGB n=20, and BPD n=20. The medical therapy group received individualized
treatment recommendations based upon the individual s needs and current ADA guidelines.
After two years, remission has occurred in 0% of the patients who were receiving medical
therapy alone, 75% who received RYGB, and 95% of patients who had undergone a BPD.15
Parikh et al., defined remission as no longer meeting the ADA criteria for type 2 diabetes
without the use of diabetic medication. This study included 48 participants n=20 in the surgical
group who could choose from RYGB, GS, or AGB as treatment options, and n=24 in the medical
therapy alone group. Subjects in the medical therapy group were educated and encouraged to
participate in group or individual sessions focusing on nutrition, physical activity, and goal
setting. In addition, these sessions reviewed at home glucose data and made adjustments to their
diabetic medications as needed. Patients were examined at 6 months and it was found that
diabetes remission had occurred in 65% of patients in the surgical group while 0% of patients in
the medical therapy group had achieved remission (p<0.0001).7
Cummings et al., defined remission of diabetes as HbA1c <6.0% while being off all
diabetes medication. There were n= 15 patients in the surgical group who received a RYGB and
n=17 in the medical therapy group. Patients in the medical therapy group were instructed in diet
training weekly for the full year of the study. They also participated in 3 supervised exercise
sessions and were encouraged to work out >2 times per week at home for the first 6 months. The
following 6 months they participated in 1 supervised workout and were encouraged to exercise
>4 days per week at home. Both groups received medical care including medication for their
diabetes through their own family practitioner based upon the ADA guidelines. This study found

that after 1 year 60% of patients who received the RYGB versus only 5.9% who received
medical therapy alone had achieved remission (p=0.002).13
In a similar study comparing RYGB to non-surgical treatment and examining remission
of type 2 diabetes Simonson et al., followed patients for an additional 2 years. This study defined
remission as having a HbA1c <6.5% and a FPG<126mg/dl. The study included 19 patients who
underwent RYGB and 19 patients who received intensive lifestyle management with
medications. The non-surgical group participated in two hour group sessions conducted weekly
during a 12-week induction phase. These sessions included supervised group exercise,
adjustments to medication, and didactic work. The participants were encouraged to limit calorie
intake to 1500-1800 kcal, exercise for 300 minutes per week, and were given diabetes
medications that are not associated with weight gain or hypoglycemia. During this trial, all
participants were receiving antidiabetic medications. After 3 years it was found that 42% of the
RYGB group had achieved remission of diabetes. 7 out of the 8 who achieved remission were
taking no antidiabetic medications. While no patients who were in the non- surgical group
achieved a remission. When comparing it is obvious that the RYGB group showed significant
improvement in remission of diabetes to the non-surgical group at 3 years (p=0.005).14 In
summary these studies provide consistent evidence that remission can be achieved more
frequently in bariatric surgery populations than medical therapy alone, the duration of
effectiveness remains in question.
Glycosylated Hemoglobin A1c levels
Glycosylated hemoglobin values are used by providers to determine the average blood
glucose levels in patients for the past 2-3 months. It is often also used as an indicator of how well

a patient s diabetes is controlled. This review identified many studies which demonstrate that
bariatric surgery is superior to non-surgical medical therapy in reducing HbA1c levels.6,7,12-19
The different surgical modalities used include RYGB 6,7,12-19, GS7,12,16-18, AGB7, and BPD15. In a
prospective randomized control trial Schauer et al., examined 150 patients who underwent either
intensive medical therapy (lifestyle changes plus medications n=50), sleeve gastrectomy (SG)
plus medication n=50, or route- en-Y- gastric bypass (RYGB) plus medication n=50. The
participants average BMI was 37 +/- 3.5, their mean A1C was 9.2 +/-1.5% suggesting
uncontrolled diabetes, and their mean duration of diabetes was 8.4 +/- 5.2 years. These patients
were examined for changes at 1 year16, 3 years17, and 5 years18. The primary endpoint for these
trials was to evaluate the number of patients who could achieve a targeted HbA1c of 6% or less.
Schauer (2012) et al., recorded that 5 of 41 (12%) in the medical therapy group, 21 of 50 (42%)
in the RYGB group, and 18 of 49 (37%) of the SG group were able to achieve a HbA1c value
less than or equal to 6%. This study show significant improvement in reaching HbA1c goals in
the surgical groups when compared to the medical therapy group (p<0.008).16 However there
was no significant difference when comparing the two surgical groups (p=0.59).16 Schauer
(2014) et al., recorded a decreased in the number of patients achieving the endpoint of the studies
at 3 year follow up. Showing that 5% of patients in the medical therapy group, 38% of patients in
the RYGB group, and 24% of patients in the GS group sustained HbA1c levels at or below 6%.
Still the surgical groups provided significant improvement when compared to medical therapy
(p=0.01).17 Additionally, this study showed that patients in the two surgical groups had a
significant absolute decrease of 2.5 percentage points in HbA1c levels sustained at 3 years while
the medical therapy group showed a reduction of 0.6 percentage points.17 Schauer (2017) et al.,
showed that after 5 years 29% of patients who received gastric bypass, 23% of patients who

received a sleeve gastrectomy, and 5% of patients who received intensive medical therapy alone
were able to reach an HbA1c level of 6% or lower. Showing that SG and RYGB significantly
improved sustained HbA1c levels superior to that of medical therapy alone at 5 years (p<0.03).18
Although most research indicates that bariatric surgery lowers HbA1c levels more
effectively than medical therapy alone, one article found no significant difference between the
methods for helping patients achieve HbA1c levels <6%.14 In a prospective randomized trial
Simonson et al., compared 38 patients (n=19 in RYGB group and n=19 in nonsurgical group)
whose mean BMI was 36 +/- 3.4, HbA1c was 8.5 +/- 1.3% and their duration of diabetes was
10.6 +/- 6.6 years. Participants in the non-surgical group received intensive medication and
weight management therapy. While the surgical group received medication therapy and RYGB
surgery. After 3 years there were no significant differences between the surgical group and nonsurgical group in the number of patients who achieved a HbA1c <6% (p=0.104)14, which differs
from Schauer (2014)17 findings at 3 years.
Only one study provided a significant difference in HbA1c levels when comparing the
different surgical modalities used to treat diabetes. Mingrone et al., found at 2 year follow up the
average percent change in HbA1c levels from a baseline of 8.65% had decreased by 0.72% in the
medical therapy group, 2.16% in the RYGB group, and 3.71% in the BPD group. The two
surgical groups significantly improved HbA1c when compared to the non-surgical group
(p=0.003, p<0.001) respectively. However, it was also found that the BPD group significantly
outperformed the RYGB group (P=0.001) in decreasing HbA1c levels .15 Therefore some
providers may want to consider BPD in patients that remain at significant risk due to a lack of
blood glucose control. However, surgical risks and side effects between the two surgeries should
be weighed when making the decision.

Antidiabetic Medication Use
It is important to distinguish the difference of medication use between bariatric surgery
and medical therapy groups. By doing so providers can validate their suspected hypothesis that
bariatric surgery allows for better blood glucose control while eliminating medication use as a
potential risk for biases in the results between both treatment options. This review article
identified many studies which showed a significant and superior decrease in glycemic
medication use following bariatric surgery when compared to medical therapy alone. 6,12-14,16,19 In
addition to less glycemic medication use, 4 studies examined total medication use and found
significant decreases in hypertension and hyperlipidemia medications following bariatric surgery
versus medical therapy.13,14,16,19 This review will remain focused on the findings for glycemic
medication use.
In a prospective randomized control trial Schauer (2012) et al, examined 150 patients and
found that after 1 year, the percentage of patients using insulin in the medical therapy did not
have a significant change, though it did decrease from 51% of patients to 38%. While insulin use
in the RYGB group had decreased from 46% of patients at baseline to 4%. Similar results were
found in the SG group who showed 45% of patients using insulin at baseline decreased to 8% at
one year. When comparing the two surgical groups to medical therapy the significant decrease in
insulin use was apparent (p<0.001 for both comparisons).16 In that same cohort of patients
Schauer (2017) et al., found similar results at their 5 year follow up showing that approximately
89% of patients in the two surgical groups were not using insulin for glycemic control and
patients were still able to maintain an average HbA1c of 7%. Whereas 61% of patients in the
medical therapy group were not taking insulin at 5 years with an average HbA1c of 8.5%,
suggesting uncontrolled diabetes and the need for increased treatment.18

In another study examining medication use between bariatric surgery and medical
therapy groups Serrot et al., at the University of Minnesota, performed a retrospective review on
34 patients (n=17 in RYGB, and n=17 in non-surgical group). Participants in the RYGB surgical
group were treated with medications, dietary education, and lifestyle counseling. The nonsurgical group participants were treated with medications focused on controlling hyperglycemia,
and with counseling regarding nutrition, exercise, and weight management. The RYGB and nonsurgical groups had comparable medication use at baseline. After 1 year, the RYGB group was
taking significantly less medication for glycemic control, with 71% of patients taking fewer
medications compared to 6% in the non-surgical group (p<0.001). Important to note though was
that 3 of the 9 patients in the surgical group who choose not to take glycemic medications had a
HbA1c >7% which suggests the need to return to medication therapy.19
Changes in insulin sensitivity/Pancreatic Beta cell function/Incretins
As aforementioned the exact mechanism by which bariatric surgery improves insulin
sensitivity, pancreatic beta cell function, or incretin release is unknown. Regardless of the
mechanism, an improved beta cell function, incretin release, and increased insulin sensitivity is a
welcomed outcome for any patient seeking treatment for type 2 diabetes. This review identified
two studies which provide data showing that bariatric surgery significantly improved insulin
sensitivity 7,12, beta cell function12, and increased incretins12 when compared to medical therapy
alone.7.12 The first study conducted by Parikh et al., examined 44 patients (n=20 in surgical
group, n=24 in medical therapy group) through a prospective randomized control trial. Patients
in the surgical group were able to choose from RYGB, SG, or AGB as surgical modalities while
the medical therapy group utilized intensive lifestyle interventions focused on diet, physical
activity, and counselling. Both groups received medication treatment for their diabetes according

to current guidelines. Parikh et al., unutilized a formula called The Homeostatic Model of Insulin
Resistance (HOMA-IR); to assess changes in insulin resistance between the two groups at 6
months follow up. It was noted that the surgery group had decreased HOMA-IR by 4.6 while the
medical therapy group saw an increase in insulin resistance of 1.6 (p=0.0004). When performing
a 75g oral glucose test, patients who had surgery recorded an average blood glucose of 130
mg/dl compared to the medical therapy group who averaged 306 mg/dl after 2 hours (p<
0.0001).7
In the second study, Kashyap et al. conducted a randomized control trial on 54 patients
(n=17 intensive medical therapy group, n=18 in RYGB group, and n=19 in SG group). Changes
in insulin sensitivity, beta cell function, and incretin release between the surgical and medical
groups were examined. The medical therapy group treatment followed ADA guidelines and used
the latest U.S. Food and Drug Administration approved medications to treat their diabetes.
Patients who were treated with surgery also received diabetes medications in line with ADA
guidelines. Utilizing the (matsuda index) in non insulin- using patients, this study recorded that
median values for insulin sensitivity increased at 24 months in the RYGB group (n=9) by 2.7
fold when compared to medical therapy alone (p<0.001). The SG group (n=10) recorded a 1.2fold increase and there was no change recorded in the medical therapy group alone. This study
also examined changes in median values for pancreatic beta cell function using an oral
disposition index at 24 months. The patients who received RYGB saw a 5.8 fold increase in
median beta cell values when compared to medical therapy alone while there was no significant
increase from the GS group. Through a sub study cohort correlation these researchers found that
the beta cell changes were significantly related to the change in percentage of truncal fat
(P=0.0013) and body weight (p<0.001). Lastly this study examined median levels of Glucagon-

like- peptide-1 (GLP-1) changes between the surgical and medical therapy group at 24 months.
Taking into account fasting, this study found GLP-1 median levels 60 minutes after mixed-meal
injection (8 oz of Boost drink) increase drastically after RYGB (12.5 vs 2 pmol/L; p<0.001), SG
(7.3 vs 2.4 pmol/L; p<0.01, and did not change with the medical therapy group (1.5 vs 1.4
pmol/L; p=not significant). Suggesting that bariatric surgery effectively increases incretin release
up to two years following surgery when compared to medical therapy alone.12
Comorbid Risk factors
In addition to improving blood glucose, bariatric surgery can provide changes in weight,
BMI, blood pressure, and lipid levels which have all been indicated as risk factors for significant
sequelae in diabetic patients. Many studies provide data suggesting that bariatric surgery is
superior to medical therapy alone in providing and sustaining a decrease in weight or BMI.6,7,12-19
Weight loss difference between bariatric surgery and medical therapy are often seen greatest at 1
year follow up14 and though the difference in weight loss between the groups narrows, bariatric
surgery is still superior at 5 years.18 The greatest difference in weight and BMI changes are
found with patients who have undergone BPD due to the malabsorption effect of this surgery. 15
Conflicting evidence exists among studies that examined blood pressure changes in
bariatric surgery groups versus medical therapy. With emerging evidence the ADA
recommendations have become more relaxed in recent years and are now recommending a
systolic blood pressure (SBP) goal of <130 for patients with type 2 diabetes.6 Two studies
reported a significant decrease of SBP in the surgical groups when compared to medical
therapy.6,13 Both of these studies examined RYGB and followed up with patients at 1 year.
However, these results were not shared among 3 other studies who used the same treatment

modality and followed patients at 1 to 5 years.7,18,19 These findings suggest that bariatric surgery
should not be used solely for the indication of controlling hypertension among diabetic patients.
Many studies utilized lipid panel values to assess for changes among surgical groups and
those who were given medical therapy.6,7,12-16,19 One study that examined changes at 6 months
between the two groups found no significant changes in lipid levels however patients in this
study also had baseline levels that were normalized before treatment.7 There were 3 studies that
compared RYGB to medical therapy with a 1 year follow up and only one found an increase in
high density lipoproteins13 while there were no significant differences noted in low density
lipoproteins, total cholesterol, or triglycerieds.6,13,19 Two studies examined difference in lipids at
2 years.12,15 Interestingly HDL significantly increased with RYGB in one study15 but did not
change significantly with the second study.12 In evaluations of longer follow up times 3 studies
examined outcomes of RYGB and SG at 3 years14,17 and 5 years.18 These articles provided data
that was different from early studies showing a significant decrease in in LDL14, total
cholesterol14, triglyceries14,17,18, and a significant increase in HDL.14,17,18 This evidence suggest
the need to wait 3-5 years before evidence of bariatric surgery shows superior benefit compared
to medical therapy in lipid levels.
Safety and Side Effects of Bariatric surgery
Common questions found among patients who have developed uncontrolled diabetes and
meet criteria for bariatric surgery center around its safety and correlated side effects. This review
includes 2 studies which analyzed 30-day outcomes in patients who had bariatric surgery.20,21
The first study conducted by Birkmeyer et al., examined rates of complications in 15,275
patients who had undergone bariatric surgery(n=5380 in AGB group, n= 864 in SG group, and

n=9041 in RYGB group). Fatal complications occurred in 2 patients who had received an AGB
(0.04% risk), 0 patients who received SG, and 13 patients who received RYGB (0.14% risk.)
Potentially life-threatening complications, defined as venous thromboembolism, cardiac, renal,
or respiratory failure, occurred in 1.5% of patients overall. This percentage varied from 0.58% in
patients with AGB surgery to 2.1% in patients who received gastric bypass. 20
Similarly in a longitudinal assessment of bariatric surgery at 10 clinical sites in the
United States 4610 patients (n=3412 in RYGB, n= 1198 AGB) were evaluated for major adverse
outcomes.21 Major adverse outcomes included death, deep vein thrombosis, reintervention, or
failure to be discharged within 30 days and were seen in 4.1% of patients: 1% of patients who
received AGB, 4.8% who received laparoscopic RYGB, and 7.8% of those who underwent open
RYGB. When evaluated independently it was noted that 0.3% of patients had died: none of the
1198 who underwent AGB, 0.2% of 2975 who underwent laparoscopic RYGB, and 2.1% of 437
who had undergone an open RYGB. Also, deep vein thrombosis occurred at a rate of (0.4%): 3
in the AGB group (0.3%), 6 in the laparoscopic RYGB group (0.2%), and 9 in the open RYGB
(2.1%).21 These studies provided evidence that major complications do occur from bariatric
surgery. However, the relative rates in which they occur are extremely low which suggests that
bariatric surgery should be considered a safe procedure.
When considering the short term risks compared to the long term benefits of bariatric
surgery, Adams et al. in a retrospective cohort study examined 15850 individuals (n=7925 in
RYGB group, n=7925 in nonsurgical) who were matched for age, sex, and self-reported BMI.
Subjects were studied for causes of mortality at an average of 7.1 years following surgery.
Analyzing the specific cause of mortality this study showed that the RYGB group observed a
decrease in mortality rates by 56% in coronary artery disease, 92% for diabetes related deaths,

and 61% for cancer when compared to those who did not have bariatric surgery. These results
were all examined beyond 5 years from baseline which provides evidence that could be reviewed
with patients who are considering bariatric surgery as a treatment option to help control their
diabetes.22
Studies which review the safety of bariatric surgery specifically in patients with type 2
diabetes are extremely limited. This review could only identify 1 article that provided data on SG
safety outcomes in type 2 diabetic patients.23 In a retrospective cohort study Guetta et al.,
examined 984 patients (n= 841 without type 2 diabetes diagnosis, n=143 with type 2 diabetes)
for severe and mild complications. Subjects were examined at 1 week, 4 months, 8 months, and
12 months. Early complications were considered <60days post-surgery and late complications
are defined as > 60days post-surgery. Severe complications were defined as (requiring
intervention under general anesthesia, placement in an intensive critical care unit, multiorgan
failure, or death). While mild complications were defined as (any deviation from normal
postoperative course, requiring any drug therapy, parenteral nutrient, blood transfusion or
intervention not under general anesthesia.) At 1 year this study only recorded 1 death found in
the non-type 2 diabetes group, the cause of death was not reported. When comparing the two
groups through a multivariate binomial logistic regression, type 2 diabetes proved to be the only
significant variable of difference. This study noted a significant higher percentage of mild
complications seen in patients who had been diagnosed with diabetes compared to those who
were not (8.4% versus 3.8%, p=0.01) respectively. However, there was no difference in severe
complications at 1 year (p=0.615).23
In addition to examining significant and severe complications of bariatric surgery this
review utilized 2 studies which examine nutritional deficiencies and other more common side

effects of bariatric surgery.11,24 Lupoli et al., reports anemia as one of the most common side
effects seen in bariatric surgery with a prevalence between 33-49% at 2 year follow up.11 Tack et
al., reports dumping syndrome as another prevalent sequelae identifying prevalence of up to 40%
in individuals who were treated with RYGB or SG.24 Vitamin deficiencies also remain high
among patients who have undergone bariatric surgery.11,24 Most common among these deficiency
are B12(up to 62%) , folate (up to 39%), and iron (up to 44%).11,24 Vitamin deficiencies are
treatable but if left untreated they can lead to abnormal bone metabolism, fractures, neurological
dysfunction, and anemia.11 Deficiency surveillance is strongly encouraged among these patients
and should be a top priority for providers who engage in treating this population.
Discussion:
The primary purpose of this study was to examine how intensive medical management
compares to bariatric surgery in treating diabetes. The author paid special attention to glycemic
control and comorbid disease risk factors when comparing the two treatment options. This study
also examines general safety and common adverse side effects seen from bariatric surgery.
Remission:
This review article has identified that bariatric surgery is superior to medical therapy in
causing remission of diabetes, as evidenced by multiple clinical control trials.7,13-15 Remission of
diabetes without taking any antidiabetic medications occurred in as little as 6 months for patients
who were treated with RYGB, ABG, and SG while no patients saw remission in the medical
therapy group during this short time frame.7 These results remained consistent in studies who
followed patients for one13, two15, and three years14.

Two observations found upon literature review are worth noting. First, patients who
obtained bariatric surgery saw a decrease of 5% remission rates at 1 year follow up.13 Having
more strict HbA1c levels as part of remission criteria at 1 year is possibly the reason for this
difference.
Secondly, remission rates seen at three years in a RYGB group of 42%14 are markedly
lower than 75%15 recorded by Mingrone et al., at two year follow up. Though these numbers are
significantly greater than the medical therapy group, these results bring into question the duration
in which bariatric surgery shows superiority. This discrepancy may be explained by the duration
in which patients in each study were diagnosed with diabetes. The patients in the 3 year follow
up study recorded an average diagnosis of 10.6 years 14 while those who were examined at 2
years only had an average of 5 years.15 In addition, these results could be tied to patients
reverting back into old eating habits and discontinuing recommended treatment plans. To this
affect Dr. McRae commented, “Bariatric surgery is not a magic fix. It does not change people s
desires to make lifestyle changes and cannot replace healthy habits. Depending on the study,
approximately 30-63% of patients who undergo a Roux-en-Y procedure will have their type 2
diabetes go into remission within 1-5 years. Among these patients who experience diabetes
remission, 35-50% will eventually experience recurrence of the disease. Much of the patient s
ability to retain the remission status is secondary to their ability to eat healthy, maintain a high
level of activity and keep the weight off.
Hemoglobin A1c control
In addition to an increase of diabetes remission rates bariatric surgery also shows superior
control of HbA1c values when compared to medical therapy alone. Multiple studies provide data

showing that bariatric surgery modalities decrease HbA1c values 6.7.12-19 at greater rates than
medical therapy. Though the percentages of patients who reached HbA1c values of <6%
decreased over time in the surgical groups they were still found to be superior to the medical
therapy groups at 116, 317, and 518 years. The decrease in the percentage of patients with HbA1c
levels <6% overtime may suggest that at some point there is no superior effect seen with bariatric
surgery when compared to medical management.
To that effect, Simonson et al. examined 2 groups of patients, one group who received a
RYGB and one group who were treated with intensive medical management.14 This study
examined outcomes at 3 years and found that there was no significant difference in obtaining a
HbA1c <6% or <7% between the two groups.14 This result is in stark contrast to the patients who
Schauer (2014)17 examined with the same time frame and surgical modality.
Upon evaluation of these two studies there is one major difference among them that could
contribute to the cause of the subsequent outcomes. The treatments found in patients who were
among the medical therapy groups were quite different. Simonson et al., treated patients with
weekly supervised exercise and didactic sessions for the first 3 month of the trial. 14 In addition
these patients underwent weekly medication adjustments as needed, were given a hypocaloric
diet 1500-1800 kcal/day, and instructed to exercise 300 minutes per week.14 In contrast, Schauer
(2014) treated patients in the medical therapy group strictly by education of the ADA guidelines.
This group was educated with lifestyle counseling, weight management (weight watchers
program), frequent home glucose monitoring, and the use of medication as needed.17 These
patients also had a follow up every 3 months with a diabetes specialist at the Cleveland clinic. 17
The different management techniques found in these studies are specifically, observed exercise
of patients and hypocaloric diets. These changes could be a significant cause for the

improvement of HbA1c values in the non-surgical group which most likely contributed to the
lack of observing any significant difference in bariatric surgery and medical therapy in the
Simonson et al., study.
Antidiabetic Medication Use
An important factor to consider when determining superior treatment options for patients
with type 2 diabetes is the amount or number of medications being used to control this disease. It
was observed within a number of studies in this review that patients who received bariatric
surgery needed fewer antidiabetic medications to control glycemic levels when compared to
medical therapy alone.6,12-14,16,18,19 Ikramuddin et al., examined patients who underwent RYGB or
medical therapy and found that after 1 year follow up patients in the surgical group were taking
on average 3 fewer medications to control their diabetes.6 Schauer (2012) et al., followed
patients for 1 year and found that patients in the medical therapy group actually had an increased
average number of medication being used for hyperglycemia while those who received RYGB or
SG showed significant decreased (P<0.001).16 Similar results were noted among RYGB patients
at 3 year follow up which showed that bariatric patients were still taking on average 1.4 less
medications for glycemic control while the medical therapy group in this study had increased by
an average of 0.7 medications.14 The mechanism by which bariatric surgery improves glycemic
control has yet to be discovered but studies have provided correlations between bariatric surgery
and increased beta cell function, incretin release, and insulin sensitivity 7,12. These correlations
most likely explain why bariatric surgery patients see a decrease in medication use when
compared to medical therapy alone.

It was also observed that there was a significant decrease in the percentage of patients
who needed insulin to control their diabetes following bariatric surgery when compared to
medical therapy.12,13,16,19 Schauer (2012) et al., observed that 38% of patients treated with
medical therapy alone still required use of insulin at 1 year follow up while only 4% and 8%
needed it in the RYGB and SG groups respectively.16 Cummings et al., found similar results
observing that 60% of patients in the RYGB group at baseline needed insulin which fell to 27%
at 1 year follow up. While the medical therapy group saw a decrease from 47% at baseline to
41% at one year.13 Schauer (2017) followed patients for 5 years and found that only 11% of
patients in the RYGB and SG group need insulin therapy while 39% required its assistance for
glycemic control in the medical therapy group.18 These studies provide data which suggests that
bariatric surgery is superior to medical therapy alone in reducing the percentage of patients using
insulin.
Three points felt important to evaluate during this review. First, the discrepancy between
the Schauer (2012) study16 and Cumming s et al13., findings which examined RYGB patients at 1
year and found drastically different percentages of patients still requiring insulin at 4% 16 and
27%13. The differences between these individual studies are vast and possible reasons for the
observed differences are endless; however, the most notable difference was their percentages of
patients requiring insulin at baseline in their RYGB group. Schauer (2012) recorded only 46% of
their RYGB group needed insulin at baseline while 60% of those in the Cumming et al., study
needed insulin.13,16 In addition, the number of participants were 1513 and 5016 which could also
contribute to the differences observed, suggesting that the higher the number of participants
within the study will likely increase the chances of observing more patients not requiring insulin
for glycemic control.

Second, a possible reason why at 5 year follow up the same patients observed in Schauer
(2012)16 had increased their insulin use to 11%18 instead of 4% and 8% seen at 1 year. Diabetes
is a progressive disease if not properly controlled and will return if proper diet, exercise, and
other lifestyles changes are not made. Glycemic control is difficult and sustained results largely
depend on one s ability to make and keep lifestyle changes. Regarding this topic, Dr. McRae
states “Success with diabetes care is almost exclusively based on patient s motivation to change.
There is still nothing that can replace the incredible benefits of a healthy lifestyle which not only
improves morbidity and mortality but has the potential to completely push diabetes type 2 into
remission. Patients within the surgical groups may become complacent and fail to remain active
in combating their diabetes through lifestyle changes. This change may eventually lead them
back to medications and other treatment options to help control their glycemic levels.
Third, RYGB seemed to have a slight advantage over SG in decreasing insulin use and
the total percentage of patients requiring medication. One study showed that 66% percent of
patients who received RYGB were able to achieve glycemic control while taking no antidiabetic
medications compared to only 38% seen in SG.12 In addition, another study noted that after 1
year follow up 8% of patients who received SG needed insulin for glycemic control compared to
4% who received RYGB .16 The difference noted within these two surgical groups could be
related to the changes in weight loss following these two different surgical modalities. In both
studies the RYGB group lost more weight than the SG group did. Other studies 7,12 have provided
evidence that a decrease in weight is related to improved insulin sensitivity. Therefore, the
reason for decreased insulin use and a greater percentage of patients off antidiabetic medications
most likely could be attributed to the changes in weight observed in the RYGB compared to the
SG groups.

Changes in insulin sensitivity/Pancreatic Beta cell function/Incretins
The reason behind increased rates of remission, better HbA1c control, and decreased
hyperglycemic medication use lies in the metabolic change bariatric surgery creates in diabetic
patients. Following bariatric surgery through an unknown mechanism patients observe improved
beta cell function, insulin sensitivity, and increased incretin release significantly more than those
who were treated with medical therapy alone.7,12
In addition to incretins secretion and improved insulin sensitivity, RYGB patients
observed a 5.8-fold increase in median beta cell functions when compared to the medical therapy
group.12 However there was no significant change noted in the SG group as opposed to the
medical therapy group in this study.12 Through a sub cohort study changes in beta cell function
were attributed to decreased truncal fat and body weight.12 However, there were no significant
changes in weight or truncal fat noted between the surgical modalities.12 Therefore, the
difference in these surgical groups effect on beta cells must be explained through other
mechanisms which likely fall into complex nutrient absorption changes.
Overall improved beta cell function will secrete more insulin thus causing an increase in
incretins levels and improved insulin sensitivity. The changes manifest in cellular proteins
brought on by a decrease in fat surrounding organs will also improve insulin sensitivity. All of
these changes seen in bariatric patients lead to improved glycemic control, decreased medication
use, and higher rates of remission when compared to medical therapy alone.
Comorbid Risk Factors

This study concludes with previous research that bariatric surgery is superior to medical
management alone in the reduction of weight and related changes to BMI.6,7,12-19 BPD proved to
be the surgical modality which offered patients the greatest decrease in body weight and BMI. 15
This result can probably be attributed to the nature of this surgery which only leaves a very short
window to allow absorption of nutrients whereas other surgical modalities involve less extreme
measures or allow greater areas of bowel to be included for nutrient absorption. Though proven
to have an increased weight loss BPD also is related to increased number of associated side
effects such as dumping syndrome and malabsorptive defiencies.11,24 Therefore patients and
providers should consider the benefits and risks when weighing this treatment option.
Previous studies have concluded that blood pressure was significantly decreased in
bariatric surgery when compared to medical management alone.6,13 However, these results were
not conclusive with 3 studies found in this review showing that there was not significant
difference among these two groups. 7,18,19 All of these studies included patients who underwent
RYGB but different follow up times existed. The earliest study which examined blood pressure
changes had patients follow up at 6 months.7 This study recorded no significant changes between
the surgical and medical therapy groups.7 Upon further review of this article it was noted that
this finding could be a potential weakness. The patients who were included had normotensive
blood pressures at baseline which most likely led to this insignificant result.7 Additionally, this
study had a relatively short time frame for follow up at six months when previous studies who
made positive claims examined patients at 1 year.
Three studies examined RYGB patients at 1 year for changes in blood pressures. 6,13,19
Serrot et al., in a retrospective review concluded that there was no significant change in BP in the
surgical group compared to the medical therapy alone.19 In contrast, one additional article

reported a 28% increase in the percentage of patients who achieved a SBP <130 which was
significantly more than the non-surgical group.6 Also, one other article found a significant
decrease in SBP in the RYGB group, which decreased from 129 to 110mmHg on average with
no significant change in the non-surgical group13. The major difference among these studies is
population size. Two studies which report a significant change had a total of 72 patients, 6, 13
while only 17 patients19 were recorded in the article which disagreed. An increase in population
size could possibly explain the difference found in these articles. In addition to an increase in
population size, Ikramuddin et al. studied patients in multiple centers and international locations
which attributed to the strength of this study s findings.6 In contrast, the Serrot et al. study, which
had a limited number of patients, also completed the whole trial at the University of Minnesota
which could have led to selection bias that swayed this studies results.19
Lastly one study examined blood pressures at 5 years and found no significant difference
between the surgical and medical therapy groups.18 Therefore, even if a change in blood pressure
is significantly more in patients who obtain bariatric surgery it is difficult to determine the time
frame at which these results become null when compared to medical therapy alone.
Articles within this review do not offer data or show significant reasons why blood
pressure changes exist from bariatric surgery though it can be assumed it is due to diet changes
and a decrease in weight. However, providers and patients should be aware that this review
shows inconclusive evidence of significant blood pressure changes at 1 year when examining
bariatric surgery patients as opposed to medical therapy alone. This review agrees that a decrease
in blood pressures following bariatric surgery occurs, however, these changes are not
consistently found to be superior to medical therapy alone.

Lastly, multiple studies were interested in lipid changes found in bariatric surgery and
how they compared to medical therapy alone. Studies examined results at 6 months7, 1 year,6,13,19
2 years,12,15 3 years,14,17 and 5 years18. Studies which occurred between 6 months and 2 years
showed fairly consistent results revealing no significant changes in LDLs, triglycerides, and total
cholesterol between the two treatment groups.6,7,12,13,19 Only two studies provided data which
showed significant improvement in high density lipoproteins within the first two years following
treatment.13,15 This change in HDL could possibly be explained in one study due to it including
BPD as a surgical modality15 whereas the other studies only used RYGB,6,11,19 SG,7,12 and ABG7.
BPD is known to cause an increased weight loss when compared to other bariatric surgery
modalities. As weight loss is associated with increased HDL levels this could explain the
observed significance. In addition to an increased weight loss Cumming et al., studied patients
with a BMI less than 3513 while those studies which did not find significant changes in HDL
levels among the surgical group compared to medical therapy included patients with BMI
averages above 35.6,7,12,19 Having a lower BMI at baseline suggests a possible healthier
population more apt to see increases in HDL levels from bariatric surgery then simply medical
therapy alone.
In studies which examined patients at 314,17 and 5 years18 results showed decreased levels
of LDL14, total cholesterol14, triglyceries14,17,18, and a significant increases in HDL.14,17,18 These
levels were found to be superior in patients who had undergone bariatric surgery when compared
to those receiving medical therapy alone.14,17,18 Elevated LDL, TC, and TG levels are associated
with significant complications in diabetic patients and can lead to life threatening outcomes.
Therefore, medical providers monitor these levels closely and follow individualized algorithms
to help decrease chances of significant sequelae. This review was able to observe that bariatric

surgery begins to show superiority at 3 to 5 years when compared to medical therapy. The reason
significant changes in lipid values were not observed until 3-5 years remains a mystery and
would not correlate to changes in metabolism or weight loss as these are significantly affected in
as early as 6 months.7 Further studies should be called upon to examine the reasoning behind
these findings.
Safety and Side Effects of Bariatric Surgery
Due to the nature of the surgeries and associated side effects, which have long been
discussed in the medical community, some patients neglect to consider bariatric surgery as a
modality to help control their diabetes. One review study examined 15,275 patients who
underwent AGB, RYGB, and SG. After 30 day follow up, when most severe complication have
occurred, only 1.5% of patients experience potentially life threatening complication.20 Higher
rates of complications were observed in the RYGB group compared to SG and ABG groups.20 In
addition to higher rates of severe complications like venous thromboembolism, cardiac, renal,
and respiratory failure the RYGB group observed higher death rates.20 This comes as no surprise
due to the invasive nature of RYGB surgery as compared to SG and ABG. Patients in this study
had significant risk factors for complications in surgery like an averaged BMI of 46 which put
them into the morbidly obese category.20 Even with an increased risk, the death toll following
RYGB in this study was 0.14%, which equates to just over a tenth of a percent chance of dying
from this procedure.20 An additional review article examining 4610 patients found that bariatric
surgery carried a 4.1% risk of severe complications however this number is probably inflated due
to the fact that this study included operative reinterventions as severe complications.21 It was still
determined that the overall mortality rate among bariatric surgery patients was 0.3%. 21
Interestingly, this study found that extreme BMI values, an inability to walk 200 feet, and history

of thromboembolism, or sleep apnea correlated with increased complication rates.21 Though
these studies only identify complications up to 30 days they observed a large population of
patients and concurred with findings made by previous research that that bariatric surgery is
relatively safe. When asked about the safety of bariatric surgery Dr. McRae stated “It is
generally considered a very safe procedure. Although Roux-en-Y surgeries do show more
patient s that achieve remission of their diabetes, there are more risks involved with the
procedure compared with the Gastric Sleeve. Only one study could be identified which
examined the safety of bariatric surgery in diabetic patients.23 Following patients for 1 year it
was noted that diabetic patients had a slight increase in minor complications. 23 No significant
difference in severe complications were noted when compared to those without diabetes. 23
Therefore, patients and providers alike may conclude that bariatric surgery is safe not only in the
general populations but also in patients with diabetes.
When examining the long term benefits versus risks following bariatric surgery, one
study examined patients for an average of 7.1 years following surgery, causes of mortality were
observed.22 This study noted a significant decrease in mortality rates caused by coronary artery
disease, diabetes, and cancer in those who had a RYGB. Reduction in coronary artery disease
and diabetes death can be correlated with a decrease in lipid values and better glycemic control
following bariatric surgery. This study noted that the decrease in cancer related death is due to a
decrease in obese patients.22 Previous research has shown considerable evidence that an
increased risk of cancer is associated with obesity.22 Another possible cause which contributes to
less cancer related deaths following bariatric surgery is that cancer screening exams may
improve with weight loss.22 This study, though not solely examining patients with type two
diabetes, provides patients with the knowledge of long term benefits of bariatric surgery that may

aid them in making their decision whether or not to pursue surgery as a possible treatment
option.
Lastly, this study, like others,11,24 concludes that bariatric surgery possesses potential
risks of nutritional deficiencies, anemia, dumping syndrome, abnormal bone metabolism and
potential neurological symptoms. These risk factors are treatable and should be monitored by the
providers who take care of these surgical patients. Bariatric surgery modalities which bypass the
stomach or portions of the small bowel like RYGB and BPD are more commonly associated with
complications.11,24 All in all, bariatric surgery is safe and through proper surveillance with follow
up visits patients can avoid or at least treat these common nutritional complications.
Limitations within each article were plentiful. The sample size was extremely small for
several studies which examined the comparison between bariatric surgery and medical therapy in
treating diabetes. Many studies had less than 100 participants overall, which makes it difficult to
draw conclusions that can be applied to broad populations. In addition to small populations, it
was noted that most studies in this review had a significantly higher proportion of women over
men. This could potentially sway results or at least detract from the number of conclusions that
can be applied to male patients with diabetes. Other limitations include many of the studies
differing widely in the duration of diabetes among the examined patients which could have
altered rates of remission and other levels of glycemic control. Variations in medical therapy
existed among studies which could have led to significant findings in some studies between the
two treatment groups but not in others. Due to the individualized nature of diabetes treatment and
the significant variations in medications used, an exact comparison among the medical therapy
and surgical groups between studies would be impossible. This makes observed results
extremely generalized and less specific. Some studies examined minority populations, which

creates difficulty when applying results to the general population. Certain cofounding factors
were unable to be eliminated. Many of the patients with diabetes are also diagnosed with other
diseases. These studies did not examine other diagnoses in addition to diabetes on an individual
basis, which could have related to reported changes. Lastly, and probably the most important
limitation observed is the limited duration of follow up found among the studies. An extremely
limited number of studies exist which reviewed outcomes in diabetic patients following bariatric
surgery beyond 2 years. Which leaves practitioners and patients questioning on the duration of
time that surgery may be effective.
Conclusion:
Current literature demonstrates that bariatric surgery is an effective treatment option for
diabetes. Especially, for patients who have been diagnosed with obesity, struggle with glycemic
control, and are unable to make significant lifestyle changes. Bariatric surgery supplies patients
with higher rates of remission from diabetes when compared to medical therapy alone. In
addition, bariatric surgery proved superior in controlling HbA1C levels, decreasing weight, and
lowering the amount/number of medications used by patients for glycemic control. Interestingly,
patients who have undergone bariatric surgery observe improved beta cell function, insulin
sensitivity, and increased incretin release. Contrary to previous research hypotheses blood
pressure changes did not prove to be significantly better in the surgical groups when compared to
medical therapy. Another noteworthy conclusion was made evident by the patients lipid
profiles, which were not consistently superior in the surgical group until 3-5 years following the
operation. Specifically, patients observed a decrease in total cholesterol, low density
lipoproteins, and triglycerides, while high density lipoproteins were found to significantly
increase. Patients who obtain bariatric surgery are at risk of nutritional deficiencies, anemia,

dumping syndrome, abnormal bone metabolism and potential neurological symptoms. In
addition, patients who are diagnosed with diabetes may expect to see higher rates of minor
complications following bariatric surgery compared to those who do not have diabetes. However,
patients with diabetes do not experience higher rates of severe complications. In general,
bariatric surgery is a very safe procedure with exceptionally low rates of significant
complications or death. Long term benefits following surgery include a decreased death rate
from coronary artery disease, diabetes, and cancer. When Dr. McRae was asked about his
conclusions regarding this topic he stated: “Bariatric surgery is an excellent option to jumpstart
the weight loss process. Even with weight regain over the years and reoccurrence of diabetes,
patients tend to regain weight slower, require less medication, and their diabetes process does
better in the long run. Bariatric surgery is by far most successful when combined with lifestyle
interventions and appears to also be a good option for those who aren't able or willing to make
intensive lifestyle changes. Patients and providers alike should consider and review bariatric
surgery as a possible treatment option for uncontrolled diabetes. Patients must weigh the risks
against long term benefits while making their decision in pursuing surgical options as treatment.
Future research involving a significant number of participants diagnosed with diabetes
who qualify for bariatric surgery is needed. An ideal prospective study would include at least
1000 patients from different ethnic backgrounds with an equal number of men and women.
Making sure to avoid significant baseline difference, cohorts should be matched by: weight/BMI,
duration of diabetes diagnosis, A1C levels, insulin use/ number of medications, blood pressures,
lipid profiles, race, age, and sex assigned at birth. Participants in the medical therapy group
should be treated to ADA standards, preferably observed exercises, premade provided meals or
structured standardized nutrition plan, and strict follow-up on medication use including quarterly

follow up appointments to manage medications and examine lab values with physicians not
involved in the study. The surgical groups should undergo RYGB, BPD, GS, ABG in equal
amounts, all, receiving the same technique for the respected surgeries. Factors to be observed
should include: remission rate according to ADA standards, HbA1c levels, fasting blood glucose
values, number of medications being used to control diabetes, weight, lipid profiles (LDL, HDL,
TC, TRI), blood pressure, side effects which required medical attention and deaths. The optimal
duration would be for at least 10 years to acquire more long-term statistics. This study design
should be feasible as other studies in the past have used similar approaches but did not follow up
with patients for such an extended duration.
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Appendix A (Prompt from Dr. McRae Interview)
1) Is it difficult to manage patients with diabetes solely on medication and lifestyle
changes?

It depends. Success with diabetes care is almost exclusively based on patient s motivation to
change. Recently, several diabetes medications have been developed which contribute to weight
loss, cardiovascular and renal protection. All of these are excellent for improvement in outcomes
in morbidity and mortality. All of this aside, there is still nothing that can replace the incredible
benefits of a healthy lifestyle which not only improves morbidity and mortality but has the
potential to completely push diabetes type 2 into remission.

2) If it is yes to the previous question, how does bariatric surgery help? Who do you
suggest it for?

Habits are hard to break. Not only this, but most of our current environments make it very
difficult to lose weight and make drastic lifestyle changes. Patients who I have seen benefit the
most from surgery are those who want to exercise but are unable to due to their body habitus.
Bariatric surgery has also provided an additional option for those who have struggled making
significant lifestyle change and seek to wean off many of their medications, lose weight, improve
labs, etc. The ADA (American Diabetes Association) recommends bariatric surgery as an option
for type 2 diabetes with BMI >40 (Asia American populations have different BMI cutoffs), BMI
30-40 w/ comorbidities and difficulty achieving weight loss.

3) In your experience has bariatric surgeries changed peoples A1C, Fasting blood
glucose, or Random Glucose labs? Do you see a decrease in medication use or even a
remission in diabetes altogether? Do you see changes in lipids profiles, weight loss, and
other comorbidities?

Bariatric surgery is not a magic fix. It does not change people s desires to make lifestyle changes
and cannot replace healthy habits. Depending on the study, approximately 30-63% of patients
who undergo a Roux-en-Y procedure will have their type 2 diabetes go into remission within 1-5
years. Among these patients who experience diabetes remission, 35-50% will eventually
experience recurrence of the disease. Much of the patient s ability to retain the remission status is

secondary to their ability to eat healthy, maintain a high level of activity and keep the weight off.
With bariatric surgery, we often see a significant improvement in blood pressures, lipid profiles,
blood sugars, decrease in medication requirement, etc. There is still no randomized control trial
that I am aware of that shows an improvement in type 2 diabetes mortality following bariatric
surgery.

4) Is bariatric surgery safe? What are the major risk factors or adverse outcomes for
these patients moving forward? What is the long term outcome >5 years? Do these
patients have remission of diabetes or overtime develop the same significant issues that
once were eliminated?

It is generally considered a very safe procedure. Although Roux-en-Y surgeries do show more
patient s that achieve remission of their diabetes, there are more risks involved with the
procedure compared with the Gastric Sleeve. The bypass surgery is a much longer procedure,
there are more vitamin deficiencies, dumping syndrome, hypoglycemia, etc.

5) Any thoughts on how bariatric surgery works in treating type 2 diabetes?

The complete mechanism behind how bariatric surgery improves outcomes in type 2 diabetes is
unclear. Many patients will begin having significant drops in their blood sugar and insulin
requirements immediately following surgery before any weight loss occurs. The improvement in
lipid profiles, blood pressures and blood sugars secondary to weight loss can be explained by the
improvement in insulin resistance. When fat is removed from tissues such as the liver, muscles,
pancreas, etc. then the insulin receptor begins working much better. This allows the endogenous
insulin produced by the pancreas to start working much better and subsequently improves blood
sugars, lipid profile and blood pressures.

6) Any conclusions you wish to make on this topic?

Bariatric surgery is an excellent option to jumpstart the weight loss process. Even with weight
regain over the years and recurrence of diabetes, patients tend to regain weight slower, require
less medication and their diabetes process does better in the long run. Bariatric surgery is by far
most successful when combined with lifestyle interventions and appears to also be a good option
for those who aren t able or willing to make intensive lifestyle changes.

